Wex Medical

WEX Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing non-opioid therapies for the management of moderate to severe pain. The company's flagship product, Halneuron (Tetrodotoxin), is a highly selective blocker of voltage-gated sodium channels, specifically targeting the Nav1.7 subtype involved in pain signaling. Halneuron is currently in late-stage clinical development for indications including chemotherapy-induced neuropathic pain and cancer-related pain. By leveraging the unique properties of Tetrodotoxin, WEX aims to provide effective pain relief without the side effects and addiction risks associated with opioids. The company operates as a subsidiary of CK Life Sciences and is headquartered in Vancouver, Canada.